Annovis Bio Announces \$10 Million Underwritten Offering of Common Stock and Warrants

Date: April 9, 2026
Location: Malvern, Pennsylvania

Key Points for Investors

• Offering Details: Annovis Bio, Inc. (NYSE: ANVS) has announced the pricing of an underwritten offering consisting of 5,263,156 shares of common stock and accompanying warrants to purchase up to the same number of shares.
• Combined Offering Price: Each share of common stock, together with a warrant, is offered at \$1.90.
• Warrant Terms: Each warrant is exercisable for one share of common stock at an exercise price of \$2.50 per share. Warrants are exercisable six months after the issue date and expire five years and six months after issuance.
• Total Gross Proceeds: Annovis expects to receive approximately \$10 million in gross proceeds, excluding potential proceeds from warrant exercises.
• Closing Date: The offering is anticipated to close on or about April 10, 2026, subject to customary closing conditions.
• Bookrunner: Canaccord Genuity is acting as the sole bookrunner for this offering.
• Use of Proceeds: The net proceeds will be used for:
  • Continued clinical development of the lead compound, buntanetap, in a Phase 3 study for Alzheimer’s disease
  • Working capital
  • General corporate purposes
• Offering Structure: All shares and warrants are offered by Annovis and are issued separately but must be purchased together. The transaction is conducted under a shelf registration statement (Form S-3) previously filed and declared effective by the SEC.
• Access to Prospectus: Investors can obtain the prospectus supplement and base prospectus on the SEC’s website or directly from Canaccord Genuity.

Potential Impact on Shareholders

• Dilution Risk: The issuance of new shares and warrants will increase the number of outstanding shares, which may result in dilution of existing shareholder value.
• Price Sensitivity: The offering price (\$1.90) and warrant exercise price (\$2.50) are below recent trading prices, which could pressure the share price in the short term.
• Strategic Financing: The capital raised is earmarked for continuing Phase 3 clinical trials for buntanetap, Annovis Bio’s lead candidate targeting Alzheimer’s and Parkinson’s diseases. Positive trial developments could offset dilution concerns and drive future share value.
• Warrants Exercise: If warrants are exercised, the company could receive additional capital, but this would further dilute existing shareholders.
• Regulatory Compliance: The offering is registered with the SEC and complies with securities laws, providing transparency and protection to investors.
• Forward-Looking Statements: The company cautions that actual results may differ from expectations due to risks and uncertainties highlighted in its SEC filings, including Annual and Quarterly Reports.

About Annovis Bio

Annovis Bio is a Phase 3 clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins—APP and amyloid beta, tau, alpha-synuclein, and TDP-43—using a specific RNA-targeting mechanism. The company aims to halt disease progression and improve cognitive and motor functions in patients.

Investor Contact

Contact: Alexander Morin, Ph.D., Director, Strategic Communications
Email: [email protected]
Address: 101 Lindenwood Drive, Suite 225, Malvern, PA 19355
Website: www.annovisbio.com

Disclaimer: This article contains forward-looking statements based on information provided by Annovis Bio. Actual results may differ due to risks and uncertainties described in the company’s SEC filings. Investors are encouraged to review official documents and consult with financial advisors before making investment decisions. This article is for informational purposes only and does not constitute an offer to buy or sell securities.

View Annovis Bio, Inc. Historical chart here